Myeloma Patients Europe

Startpagina
België
Brussels
Myeloma Patients Europe

Myeloma Patients Europe is an umbrella organisation of myeloma and AL amyloidosis patient groups

Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma patient groups and associations from across Europe. MPE was formed following the merger in 2011 of the European Myeloma Platform and Myeloma Euronet. MPE is registered as a non-profit organisation (AISBL) under Belgian law and its headquarter is located in Brussels. MPE has a number of broad aims including:
• Collaborating on projects to the benefit of the myeloma community
• Exchanging information and best practice
• Developing existing patient groups and encouraging and facilitating the setting up of new groups
• Helping to shape appropriate health- related policies and initiatives on a European and national level
• Ensuring patients across Europe receive timely access to new treatment
• Stimulating and promoting patient- centred research and clinical trials
• Developing a strong evidence base for the needs and wants of patients and their role in research
• Providing information, educational and outreach programmes to member groups

To meet its aims and in addition to its membership, MPE works directly with healthcare professionals, reimbursement authorities, regulators, politicians, pharmaceutical companies, the media and anyone involved in the ‘myeloma community’.

05/11/2025

- Self-care is not selfish. Whether it is reading a book, spending time with loved ones, or simply resting, make time for activities that bring you joy and peace. Your mental wellbeing is just as important as your physical health.

03/11/2025

- As we reach November and move into winter, remember to take extra care to prevent infection.
Regular hand washing, avoiding crowds when possible and keeping up with recommended vaccinations can help protect your health.

Find out more about reducing your infection risk when living with myeloma
https://f.mtr.cool/jnuyrheyro

28/10/2025

- Have you explored our Treatment Navigator? This tool helps you find and locate clinical trials and treatment options for almost 50 countries. You can use the navigator to help ask the right questions and have informed discussions with your healthcare team.

https://f.mtr.cool/mhzwlnbazq

27/10/2025

Myeloma is a relapsing-remitting cancer, meaning patients may experience periods of remission followed by relapse. Understanding your disease course helps you prepare and make informed decisions with your healthcare team. Find out more on myeloma treatment.

https://www.mpeurope.org/treatment-of-myeloma/

26/10/2025

AL amyloidosis is one of many types of amyloidosis. This is a rare, but serious condition where abnormal proteins accumulate in organs, causing them to malfunction. It can affect the heart, kidneys, liver, and nervous system.
Because it is so rare and symptoms can be vague, diagnosis is often delayed, or it can be confused for something else. On average, patients see multiple doctors before receiving the correct diagnosis.
Raising awareness helps more people recognise symptoms earlier and seek appropriate medical care. Find out more by reading our infographic on the signs and symptoms AL amyloidosis:
https://f.mtr.cool/bvqujsfhvv

26/10/2025

Partnership with Myeloma UK

Anna knew something was not right. She was experiencing constant fatigue, unexplained pain, and regular infections.
Like many patients, Anna faced delays, uncertainty, and the challenges of navigating a complex healthcare system whilst feeling unwell. Some of her symptoms seemed like signs of getting older, while others were harder to explain. After a long time and several doctor visits, she received a diganosis of AL amyloidosis.

Anna’s advice: get your symptoms checked out! Watch her story and comment below if you are surprised or can relate to this yourself.

26/10/2025

Today is World Amyloidosis Day.

Amyloidosis is a group of rare and serious conditions affecting multiple organs. Early diagnosis is crucial to avoid organ failure.

That’s why we have developed a diagnosis pathway to help patients obtain a diagnosis as early as possible. Discover our pathway to diagnosis here:
https://f.mtr.cool/hrcftmgtos

Together with , and other patient organisations we are raising awareness and advocating for better access to diagnosis and treatment across Europe.

24/10/2025

This Sunday is
Join us and to raise awareness about AL amyloidosis.
Together, we are working to improve diagnosis, treatment access, and support for patients in the UK and across Europe.

Discover our infographics related to AL amyloidosis here:
- What is AL amyloidosis?
- Signs and Symptoms
- Myeloma and AL amyloidosis

https://f.mtr.cool/xdzpiktonr

23/10/2025

We’re proud to share that Bronagh Scott, a myeloma patient from Northern Ireland and current participant in the MPE Advocate Development Programme, spoke today at the European Cancer Organisation's Community 365 Roundtable: Sustaining Our Oncology Professions – Meeting Their Needs.

Bronagh took part in Session 1: “Cancer Workers on the Front Line: Nurses in Focus,” where she drew on her unique, dual perspective as both a former senior nursing executive and a myeloma patient.

Having held several senior Nursing and Executive Nurse Director positions across the UK, Bronagh was diagnosed with multiple myeloma in 2023. In her remarks, she highlighted the vital role of nurse specialists in ensuring high-quality patient care, sharing how her own nurse specialist made a profound difference in her treatment journey.

She also reflected on the growing challenges in the nursing workforce, including the decline in training and recruitment of new nurses, and emphasised the urgent need for health systems to invest in and promote nursing specialisations. As she noted, nurse practitioners are often the first point of contact for patients, playing a pivotal role in connecting them to resources and guiding them through every step of their care journey.

We thank Bronagh for her powerful advocacy and for continuing to be a voice for both patients and the healthcare professionals who care for them.

It just so happens that we are currently taking applications for the next cohort of the MPE Advocate Development Programme. Apply now.

The MPE Advocate Development Programme (ADP) is a 12-month training programme designed to develop participants’ advocacy knowledge and skills to serve patients better locally, nationally and across Europe.

22/10/2025

- Nutrition matters!

Eating well during myeloma treatment can help maintain strength and energy. Focus on balanced meals, stay hydrated, and speak with a dietitian if you need personalised advice. Small nutritional changes can make a big difference.

https://f.mtr.cool/ezlbqfvcgo

21/10/2025

Applications are now open for the MPE Advocacy Development Programme 2026!

Deadline: 7 November 2025.

Are you passionate about improving outcomes for myeloma and AL amyloidosis patients? Do you want to ensure patient voices are fully represented across your country?

Apply or find out more now

https://www.mpeurope.org/what-we-do/capacity-building-advocacy/advocate-development-programme/

20/10/2025

Thank you for following our campaign!

Infection prevention is crucial for myeloma patients as treatments can significantly affect a patient’s immune system. If you would like to know more, our Q&As and infographics are a great place to start.

Please comment below if there is information you are looking for but cannot find.

https://f.mtr.cool/zqsobpyabt

Adres

Avenue Louise 143/4
Brussels
1050

Website

http://www.mpeurope.org/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Myeloma Patients Europe nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.